mirdametinib
Jump to navigation
Jump to search
Indications
- investigational treatment of neurofibromatosis type 1 [1]
Adverse effects
- generally well tolerated
- most common
Mechanism of action
- MEK inhibitor, inhibits persistent MAP kinase (MEK) pathway activation
More general terms
References
- ↑ 1.0 1.1 Bankhead C MEK Inhibitor Scores Big Win in Adults, Children With Neurofibromatosis Type 1. More than 40% of adults, half of children met response criteria, majority of responses durable MedPage Today Nov 15, 2024
Moertel CL, Hirbe AC, Shuhaiber HH et al ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma. J Clin Oncol. 2024 Nov 8:JCO2401034. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39514826